Compare H2O America (HTO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Regeneron Pharmaceuticals Inc — how do they compare? H2O America trades at $63.82 (market cap $2.70B), while Regeneron Pharmaceuticals Inc trades at $672.53 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 26.1× H2O America's market cap, and H2O America pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| HTO | REGN | |
|---|---|---|
Market Cap | $2.70B | $70.47B |
Sector | Technology | Health |
52-Week High | $65.43 | $812.27 |
52-Week Low | $44.44 | $545.46 |
Enterprise Value | $4.42B | $64.42B |
Dividend Yield | 2.73% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $64.52, down 1.39% today, with strong technical indicators showing a bullish trend. The company maintains solid fundamentals with 12.87% net income margin and consistent earnings beats in recent quarters. Recent news highlights upcoming Q2 2026 earnings report on July 27, 2026, and institutional buying activity. Technical analysis shows support at $62-$64 with resistance at $65-$66 levels.
HTO presents a balanced investment case with 80% analyst buy ratings and a $63.50 consensus target. The water utility's stable revenue streams and dividend yield provide defensive characteristics, though valuation multiples appear full and RSI levels suggest near-term overbought conditions. Execution on $2.7 billion capex plan remains key for growth.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
